The Supreme Court's decision not to hear Vanda Pharmaceuticals' case regarding the invalidation of patents for Hetlioz removes a layer of legal uncertainty for the company. This decision is perceived positively by the market, as it potentially safeguards Vanda's exclusive rights to Hetlioz, contributing to a rise in the company's stock price.